Fact checked by Jennifer Klump Key Takeaways The FDA approved the obesity drug Wegovy as a treatment for people with MASH ...

Chief Medical Officer of Northwestern Medicine’s Northwest region of hospitals Dr. Irfan Hafiz joins Bob Sirott to talk about when you should get your flu shot and how Omega-3 could help protect ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

A relatively old drug -- metformin -- may hold the key to preventing life-threatening illness and bolstering human longevity, ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic ...

Stocks soared on Friday after Federal Reserve Chair Jerome Powell signaled the central bank may be ready to resume cutting ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...